Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Jan 15, 2025; 17(1): 98433
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.98433
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.98433
Figure 1 Multiphasic contrast-enhanced computed tomography findings.
A: Gallbladder enlargement and wall thickening; B: Swollen hepatoduodenal mesenteric lymph nodes; C: A slightly lower density lesion.
Figure 2 Multiphasic contrast-enhanced computed tomography findings after 3 cycles of therapy.
A: The shrunken hepatoduodenal mesenteric lymph nodes; B: The shrunken lower density lesion.
Figure 3 Multiphasic contrast-enhanced computed tomography findings after 6 months of therapy.
A: The significantly shrunken hepatoduodenal mesenteric lymph nodes; B: The disappeared lower density lesion.
Figure 4 The timeline of the entire clinical course.
GC-D: Gemcitabine, cisplatin, and durvalumab; PR: Partial response; CR: Complete response.
- Citation: Chen K, Feng X, Shi Y, Li XL, Shi ZR, Lan X. Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab: A case report and review of literature. World J Gastrointest Oncol 2025; 17(1): 98433
- URL: https://www.wjgnet.com/1948-5204/full/v17/i1/98433.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i1.98433